Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.42 USD | +3.11% | -4.81% | -29.03% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.03% | 2.13B | |
-2.52% | 103B | |
+0.28% | 95.71B | |
+2.01% | 22.02B | |
-16.87% | 20.9B | |
-9.03% | 17.85B | |
-42.83% | 16.21B | |
-14.96% | 15.52B | |
+3.04% | 13.86B | |
+34.74% | 12.04B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Insider Trends: Selling By Insiders Lingers at Denali Therapeutics